O. De-l-'étude and .. , 65 8.3.1. Type d'étude et critères d'inclusion, Caractéristiques biologiques, p.66

.. Traitements-d-'entretien, 69 8.3.2.4. Effets secondaires, p.69

M. Bergeron, Pédiatrie II Neuroblastome et Medulloblastome, Standards, Options et Recommandations edn, 1999.

Y. Perel, D. Valteau-couanet, J. Michon, F. Lavrand, C. Coze et al., Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use], Arch Pediatr, issue.7, pp.11834-842, 2004.

S. Cohn, A. Pearson, W. London, T. Monclair, P. Ambros et al., The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report, Journal of Clinical Oncology, vol.27, issue.2, pp.289-297, 2009.
DOI : 10.1200/JCO.2008.16.6785

J. Michon, O. Hartmann, E. Bouffet, V. Meresse, C. Coze et al., An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma, European Journal of Cancer, vol.34, issue.7, pp.341063-1069, 1998.
DOI : 10.1016/S0959-8049(98)00061-6

S. Asgharzadeh, R. Pique-regi, R. Sposto, H. Wang, Y. Yang et al., Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification, JNCI: Journal of the National Cancer Institute, vol.98, issue.17, pp.981193-1203, 2006.
DOI : 10.1158/1078-0432.CCR-04-0496

M. Schmidt, A. Lal, R. Seeger, J. Maris, H. Shimada et al., Favorable prognosis for patients 12 to 18 months of age with stage 4

V. Minard, O. Hartmann, M. Peyroulet, J. Michon, C. Coze et al., Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology, British Journal of Cancer, vol.83, issue.8, pp.83973-979, 2000.
DOI : 10.1054/bjoc.2000.1412

M. Schmidt, J. Lukens, R. Seeger, G. Brodeur, H. Shimada et al., Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children???s Cancer Group Study, Journal of Clinical Oncology, vol.18, issue.6, pp.1260-1268, 2000.
DOI : 10.1200/JCO.2000.18.6.1260

O. Hartmann, D. Valteau-couanet, G. Vassal, V. Lapierre, L. Brugieres et al., Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution, Bone Marrow Transplantation, vol.23, issue.8, pp.789-795, 1999.
DOI : 10.1038/sj.bmt.1701737

H. Katzenstein, S. Cohn, R. Shore, D. Bardo, P. Haut et al., Scintigraphic response by 123I- metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma, J Clin Oncol, issue.19, pp.223909-3915, 2004.

N. Cheung and G. Heller, Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma., Journal of Clinical Oncology, vol.9, issue.6, pp.1050-1058, 1991.
DOI : 10.1200/JCO.1991.9.6.1050

A. Pearson, C. Pinkerton, I. Lewis, J. Imeson, C. Ellershaw et al., High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial, The Lancet Oncology, vol.9, issue.3, pp.247-256, 2008.
DOI : 10.1016/S1470-2045(08)70069-X

C. Coze, O. Hartmann, J. Michon, D. Frappaz, F. Dusol et al., NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology., Journal of Clinical Oncology, vol.15, issue.12, pp.87-153433, 1997.
DOI : 10.1200/JCO.1997.15.12.3433

R. Ladenstein, D. Valteau-couanet, P. Brock, I. Yaniv, V. Castel et al., Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study, Journal of Clinical Oncology, vol.28, issue.21
DOI : 10.1200/JCO.2009.27.3524

T. Simon, B. Hero, W. Dupuis, S. B. Berthold, and F. , The incidence of hearing impairment after successful treatment of neuroblastoma, Klinische P??diatrie, vol.214, issue.4, pp.149-152, 2002.
DOI : 10.1055/s-2002-33179

K. Matthay, J. Villablanca, R. Seeger, D. Stram, R. Harris et al., Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group, N Engl J Med, issue.16, pp.3411165-1173, 1999.

M. Schmidt, T. Simon, B. Hero, H. Schicha, and F. Berthold, The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97, Eur J Cancer, issue.11, pp.441552-1558, 2008.

M. Horn and J. Blatt, Continued Remission in Children with Neuroblastoma Despite Elevations of Urinary Catecholamine Metabolites, Journal of Pediatric Hematology/Oncology, vol.14, issue.3, pp.202-206, 1992.
DOI : 10.1097/00043426-199208000-00004

A. Garaventa, R. Luksch, S. Biasotti, G. Severi, M. Pizzitola et al., A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma, Cancer, vol.25, issue.11, pp.982488-2494, 2003.
DOI : 10.1002/cncr.11797

O. Hartmann, E. Benhamou, F. Beaujean, C. Kalifa, O. Lejars et al., Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma., Journal of Clinical Oncology, vol.5, issue.8, pp.1205-1211, 1987.
DOI : 10.1200/JCO.1987.5.8.1205

B. Yalcin, L. Kremer, H. Caron, and E. Van-dalen, High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma, Cochrane Database Syst Rev, vol.2010, issue.5, pp.6301-115

J. Pritchard, S. Cotterill, S. Germond, J. Imeson, J. De-kraker et al., High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group, Pediatric Blood & Cancer, vol.41, issue.4, pp.348-357, 2005.
DOI : 10.1016/S0308-2261(86)80011-X

D. Stram, K. Matthay, O. Leary, M. Reynolds, C. Haase et al., Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies., Journal of Clinical Oncology, vol.14, issue.9, pp.2417-2426, 1996.
DOI : 10.1200/JCO.1996.14.9.2417

F. Berthold, J. Boos, S. Burdach, R. Erttmann, G. Henze et al., Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial, The Lancet Oncology, vol.6, issue.9, pp.649-658, 2005.
DOI : 10.1016/S1470-2045(05)70291-6

R. Ladenstein, U. Potschger, O. Hartman, A. Pearson, T. Klingebiel et al., 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures, Bone Marrow Transplantation, vol.217, issue.S2, pp.28-118, 2008.
DOI : 10.1055/s-2005-836518

O. Hartmann, L. Corroller, A. Blaise, D. Michon, J. Philip et al., Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled Trial, Annals of Internal Medicine, vol.126, issue.8, pp.126600-607, 1997.
DOI : 10.7326/0003-4819-126-8-199704150-00002

R. Ladenstein, T. Philip, C. Lasset, O. Hartmann, A. Garaventa et al., Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry., Journal of Clinical Oncology, vol.16, issue.3, pp.953-965, 1998.
DOI : 10.1200/JCO.1998.16.3.953

T. Philip, R. Ladenstein, C. Lasset, O. Hartmann, J. Zucker et al., 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party, Eur J Cancer, issue.12, pp.332130-2135, 1997.

J. Pritchard, ???Megatherapy??? for advanced neuroblastoma???Rationale and role, European Journal of Cancer, vol.31, issue.2, pp.31-134, 1995.
DOI : 10.1016/0959-8049(95)00035-H

J. Lemerle, Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation, Cancer Chemother Pharmacol, vol.16, issue.2, pp.165-169, 1986.

I. Flandin, O. Hartmann, J. Michon, R. Pinkerton, C. Coze et al., Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology, International Journal of Radiation Oncology*Biology*Physics, vol.64, issue.5, pp.1424-1431, 2006.
DOI : 10.1016/j.ijrobp.2005.10.020

R. Ladenstein, C. Lasset, O. Hartmann, T. Klingebiel, E. Bouffet et al., Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation, Bone Marrow Transplant, vol.14, issue.1, pp.37-46, 1994.

K. Matthay, R. Seeger, C. Reynolds, D. Stram, O. Leary et al., Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group., Journal of Clinical Oncology, vol.12, issue.11, pp.122382-2389, 1994.
DOI : 10.1200/JCO.1994.12.11.2382

A. Tchirkov, J. Kanold, M. Giollant, P. Halle-haus, M. Berger et al., Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection, Medical and Pediatric Oncology, vol.77, issue.4, pp.228-232, 1998.
DOI : 10.1002/(SICI)1096-911X(199804)30:4<228::AID-MPO4>3.0.CO;2-I

T. Moss, M. Cairo, V. Santana, J. Weinthal, C. Hurvitz et al., Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation, Blood, vol.83, issue.10, pp.3085-3089, 1994.

B. Horn, U. Reiss, K. Matthay, A. Mcmillan, and M. Cowan, Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma, Bone Marrow Transplantation, vol.27, issue.5
DOI : 10.1038/sj.bmt.1702821

T. Simon, F. Berthold, A. Borkhardt, B. Kremens, D. Carolis et al., Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer, pp.578-583, 2011.

C. Pinkerton, T. Philip, P. Biron, D. Frapazz, P. N. Zucker et al., High-dose melphalan, vincristine, and total-body irradiation with autologous bone marrow transplantation in children with relapsed neuroblastoma: A phase II study, Medical and Pediatric Oncology, vol.28, issue.5, pp.236-240, 1987.
DOI : 10.1016/0360-3016(83)90367-X

H. Mugishima, K. Harada, T. Suzuki, M. Chin, T. Shimada et al., Comprehensive treatment of advanced neuroblastoma involving autologous bone marrow transplant, Pediatrics International, vol.8, issue.4, pp.493-499, 1995.
DOI : 10.1093/biomet/52.1-2.203

J. Finklestein, M. Krailo, C. Lenarsky, S. Ladisch, G. Blair et al., 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the childrens cancer study group, Medical and Pediatric Oncology, vol.76, issue.4, pp.307-311, 1992.
DOI : 10.7326/0003-4819-97-6-873

W. Bollag, Retinoids and cancer, Cancer Chemotherapy and Pharmacology, vol.3, issue.4, pp.207-215, 1979.
DOI : 10.1007/BF00254733

R. Seeger, S. Siegel, and N. Sidell, Neuroblastoma: Clinical Perspectives, Monoclonal Antibodies, and Retinoic Acid, Annals of Internal Medicine, vol.97, issue.6, pp.873-884, 1982.
DOI : 10.7326/0003-4819-97-6-873

J. Villablanca, A. Khan, V. Avramis, R. Seeger, K. Matthay et al., Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation., Journal of Clinical Oncology, vol.13, issue.4, pp.894-901, 1995.
DOI : 10.1200/JCO.1995.13.4.894

A. Yu, A. Gilman, M. Ozkaynak, W. London, S. Kreissman et al., Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma, New England Journal of Medicine, vol.363, issue.14, pp.3631324-1334, 2010.
DOI : 10.1056/NEJMoa0911123

URL : http://europepmc.org/articles/pmc3086629?pdf=render

K. Matthay, K. Desantes, B. Hasegawa, J. Huberty, R. Hattner et al., Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma., Journal of Clinical Oncology, vol.16, issue.1, pp.229-236, 1998.
DOI : 10.1200/JCO.1998.16.1.229

K. Matthay, J. Tan, J. Villablanca, G. Yanik, J. Veatch et al., Phase I Dose Escalation of Iodine-131???Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study, Journal of Clinical Oncology, vol.24, issue.3, pp.500-506, 2006.
DOI : 10.1200/JCO.2005.03.6400

M. Schmidt, T. Simon, B. Hero, W. Eschner, M. Dietlein et al., Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004, Nuklearmedizin, vol.45, issue.4, pp.145-151, 2006.

M. Gaze, Y. Chang, G. Flux, R. Mairs, F. Saran et al., I-Meta-Iodobenzylguanidine with Topotecan as a Radiosensitizer in Children with Metastatic Neuroblastoma, Cancer Biotherapy & Radiopharmaceuticals, vol.20, issue.2, pp.195-199, 2005.
DOI : 10.1089/cbr.2005.20.195

F. Berthold, B. Hero, B. Kremens, R. Handgretinger, G. Henze et al., Long-term results and risk profiles of patients in five consecutive trials, 1979.

T. Simon, B. Hero, A. Faldum, R. Handgretinger, M. Schrappe et al., Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy, BMC Cancer, vol.363, issue.14, p.21, 2011.
DOI : 10.1056/NEJMoa0911123

N. Gaspar, O. Hartmann, C. Munzer, C. Bergeron, F. Millot et al., Neuroblastoma in adolescents, Cancer, vol.12, issue.2, pp.349-355, 2003.
DOI : 10.4267/10608/816

R. Seeger, G. Brodeur, H. Sather, A. Dalton, S. Siegel et al., Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas, N Engl J Med, issue.18, pp.3131111-1116, 1985.

A. Canete, M. Gerrard, R. H. Castel, V. , D. Cataldo et al., Poor survival for infants with MYCNamplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience, J Clin Oncol, issue.7, pp.271014-1019, 2009.

T. Philip, J. Zucker, J. Bernard, P. Lutz, P. Bordigoni et al., Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup?, Journal of Clinical Oncology, vol.9, issue.6, pp.1037-1044, 1991.
DOI : 10.1200/JCO.1991.9.6.1037

F. Berthold and B. Hero, Neuroblastoma, Drugs, vol.16, issue.6, pp.1261-1277, 2000.
DOI : 10.1038/bjc.1986.239

URL : https://hal.archives-ouvertes.fr/hal-01402853

D. Bernardi, B. Carli, M. Casale, F. Corciulo, P. et al., Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: two studies by the Italian Cooperative Group for Neuroblastoma., Journal of Clinical Oncology, vol.10, issue.12, pp.101870-1878, 1992.
DOI : 10.1200/JCO.1992.10.12.1870

M. Kaneko, Y. Tsuchida, J. Uchino, T. Takeda, M. Iwafuchi et al., Treatment Results of Advanced Neuroblastoma With the First Japanese Study Group Protocol, Journal of Pediatric Hematology/Oncology, vol.21, issue.3, pp.190-197, 1999.
DOI : 10.1097/00043426-199905000-00006

D. Frappaz, J. Michon, C. Coze, C. Berger, E. Plouvier et al., LMCE3 Treatment Strategy: Results in 99 Consecutively Diagnosed Stage 4 Neuroblastomas in Children Older Than 1 Year at Diagnosis, Journal of Clinical Oncology, vol.18, issue.3, pp.468-476, 2000.
DOI : 10.1200/JCO.2000.18.3.468

S. Monnereau-laborde, C. Munzer, D. Valteau-couanet, S. Ansoborlo, C. Coze et al., A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age, Pediatric Blood & Cancer, vol.49, issue.6
DOI : 10.1002/pbc.21139

C. Coze, D. Plantaz, and F. Bernard, Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol, J Clin Oncol, vol.23, issue.3, pp.532-540, 2005.

S. Grupp, J. Stern, N. Bunin, C. Nancarrow, A. Ross et al., Tandem High-Dose Therapy in Rapid Sequence for Children With High-Risk Neuroblastoma, Journal of Clinical Oncology, vol.18, issue.13, pp.182567-2575, 2000.
DOI : 10.1200/JCO.2000.18.13.2567

M. Kletzel, H. Katzenstein, P. Haut, A. Yu, E. Morgan et al., Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study, Journal of Clinical Oncology, vol.20, issue.9, pp.2284-2292, 2002.
DOI : 10.1200/JCO.2002.06.060

K. Matthay, R. George, and A. Yu, Promising Therapeutic Targets in Neuroblastoma, Clinical Cancer Research, vol.18, issue.10
DOI : 10.1158/1078-0432.CCR-11-1939

URL : http://clincancerres.aacrjournals.org/content/clincanres/18/10/2740.full.pdf

E. Carpenter and Y. Mosse, Targeting ALK in neuroblastoma???preclinical and clinical advancements, Nature Reviews Clinical Oncology, vol.23, issue.7, pp.391-399
DOI : 10.1200/JCO.2005.01.388

URL : http://europepmc.org/articles/pmc3683972?pdf=render

H. Katzenstein, L. Bowman, G. Brodeur, P. Thorner, V. Joshi et al., Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study., Journal of Clinical Oncology, vol.16, issue.6, pp.162007-2017, 1998.
DOI : 10.1200/JCO.1998.16.6.2007

M. Weintraub, E. Waldman, B. Koplewitz, A. Bloom, E. Gross et al., Revel-Vilk S: A sequential treatment algorithm for infants with stage 4s neuroblastoma and massive hepatomegaly, Pediatr Blood Cancer, vol.2012, issue.591, pp.182-184
DOI : 10.1002/pbc.23186

G. Tonini, L. Boni, A. Pession, D. Rogers, A. Iolascon et al., MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children., Journal of Clinical Oncology, vol.15, issue.1, pp.85-93, 1997.
DOI : 10.1200/JCO.1997.15.1.85

A. Nakagawara, T. Sasazuki, H. Akiyama, K. Kawakami, A. Kuwano et al., N-myc oncogene and stage iv-s neuroblastoma preliminary observations on ten cases, Cancer, vol.80, issue.9, pp.1960-1967, 1990.
DOI : 10.1016/S0022-3476(73)80016-2

URL : http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19900501)65:9<1960::AID-CNCR2820650914>3.0.CO;2-4/pdf

P. Wilson, M. Coppes, H. Solh, H. Chan, D. Jenkin et al., Neuroblastoma stage IV-S: A heterogeneous disease, Medical and Pediatric Oncology, vol.57, issue.6, pp.467-472, 1991.
DOI : 10.1038/bjc.1988.24